Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 Terminated
10 enrolled
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Phase 1 Terminated
5 enrolled
Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML
Phase 1 Terminated
2 enrolled 9 charts
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
17 enrolled
Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer
Phase 1 Terminated
26 enrolled
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
Phase 1 Terminated
7 enrolled
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
Phase 1 Terminated
10 enrolled
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 1 Terminated
1 enrolled
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
Phase 1 Terminated
4 enrolled
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 1 Terminated
3 enrolled
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
Phase 1 Terminated
6 enrolled
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant
Phase 1 Terminated
1 enrolled
Gene Expression During Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Choline Magnesium Trisalicylate
Phase 1 Terminated
15 enrolled
Decitabine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase 1 Terminated
36 enrolled
SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia
Phase 1 Terminated
25 enrolled
Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia
Phase 1 Terminated
44 enrolled
Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation
Phase 1 Terminated
4 enrolled
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
Phase 1 Terminated
88 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Terminated
74 enrolled
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1 Terminated
30 enrolled
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
Phase 1 Terminated
9 enrolled
12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
Phase 1 Terminated